Characteristics of subjects
| Variable | n=68 |
| Age, n (%) | |
| 1–12 months | 15 (22.0) |
| 13–60 months | 25 (36.8) |
| 61–144 months | 8 (11.8) |
| ≥ 145 months | 20 (29.4) |
| Gender, n (%) | |
| Male | 41 (60.3) |
| Female | 27 (39.7) |
| Diagnosis | |
| Medical | 62 (91.0) |
| Surgical | 6 (9.0) |
| PELOD-2 score, n (%) | |
| <11 | 56 (82.4) |
| ≥11 | 12 (17.6) |
| Stage of shock | |
| Compensation | 29 (42.6) |
| Decompensation | 24 (35.3) |
| Refractory | 15 (22.1) |
| Vasoactive drugs | |
| Dobutamine | 8 (11.8) |
| Norepinephrine | 8 (11.8) |
| Epinephrine | 4 (5.9) |
| Norepinephrine and epinephrine | 15 (22.1) |
| Norepinephrine and dobutamine | 5 (7.4) |
| Epinephrine and dobutamine | 12 (17.6) |
| Epinephrine and dopamine | 3 (4.4) |
| Epinephrine, norepinephrine and dobutamine | 13 (19.1) |
| PICU length of stay, n (%) | |
| ≥ 7 days | 37 (47.0) |
| 8–14 days | 29 (42.6) |
| >14 days | 2 (2.9) |
| Outcome, n (%) | |
| Died | 32 (47.0) |
| Survived | 36 (53.0) |
PELOD-2, Paediatric Logistic Organ Dysfunction-2; PICU, paediatric intensive care unit.